For instance, valproic acid (VPA), a class I/IIa HDAC inhibitor, displays neuroprotective effects by increasing acetylation in tyrosine hydroxylase (TH)-positive dopaminergic neurons, while decreasing activated microglia in the striatum, improving motor function and cell survival in PD genetic model mice [111]. This evidence concerns the gene HDAC9 and Parkinson disease.